Daily Harvest Settlement Reached For $23 Million Over Recalled French Lentil + Leek Crumbles

Daily Harvest, Inc. will pay $23 million to settle a class action lawsuit filed after its French Lentil + Leek Crumbles were linked to hundreds of illnesses and liver injuries in a food poisoning outbreak two years ago.

The Daily Harvest recall was announced in June 2022, following reports of nearly 500 illnesses linked to the prepared meal-delivery service. While the cause of the hospitalizations and injuries has not been concretely identified, the manufacturer has stated it believed some consumers had an adverse reaction to ingredients used in Tara flour.

Daily Harvest delivers a variety of ready-to-blend smoothies, bowels, soups and other products, which are marketed through television ads and social media influencers. However, a number of those individuals paid to promote the products on social media are among consumers who experienced gastrointestinal illness, liver function issues, and other side effects. Some consumers also reportedly suffered severe enough injuries to require gallbladder removal surgery.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The illnesses and recall resulted in both the manufacturer and the U.S. Food and Drug Administration calling for consumers not to eat the meals and to throw them out. They also resulted in several claims being filed against the company and its Second Bite Foods, Inc. subsidiary.

The settlement resolves a Daily Harvest class action lawsuit filed by Breeanne Buckley Peni, who indicates she became “violently ill” due to gastrointestinal illness caused by the recalled crumbles, resulting in her being hospitalized. She required surgery to remove her gallbladder.

On May 2, Peni filed an unopposed motion in the U.S. District Court for the Northern District of New York, calling for approval of a $23 million class action settlement agreement (PDF) to resolve the litigation.

The settlement agreement must now be approved by U.S. District Judge Denise L. Cote.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.
Plaintiffs involved in GLP-1 vision loss lawsuits are calling for the litigation to be consolidated in New Jersey federal court, and not be bundled with existing stomach paralysis litigation.